Trial · NCT07906262
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pain Freedom at 2 Hours Postdose | 2 hours after administration of study treatment | Average treatment effect of rimegepant 75 mg relative to placebo on the proportion of participants who achieve pain freedom 2 hours after treatment of a moderate or severe migraine attack. |
| Primary | Freedom From the Most Bothersome Symptom at 2 Hours Postdose | 2 hours after administration of study treatment | Average treatment effect of rimegepant 75 mg relative to placebo on the proportion of participants who are free from their prespecified most bothersome migraine-associated symptom 2 hours after treatment. |
| Primary | Pain Relief at 2 Hours Postdose | 2 hours after administration of study treatment | Average treatment effect of rimegepant 75 mg relative to placebo on the proportion of participants achieving pain relief 2 hours after treatment of a moderate or severe migraine attack. |
| Secondary | Pain Freedom at 1 Hour Postdose | 1 hour after administration of study treatment | Average treatment effect of rimegepant 75 mg relative to placebo on the proportion of participants who achieve pain freedom 1 hour after treatment of a moderate or severe migraine attack. |
| Secondary | Pain Relief at 1 Hour Postdose | 1 hour after administration of study treatment | Average treatment effect of rimegepant 75 mg relative to placebo on the proportion of participants achieving pain relief 1 hour after treatment of a moderate or severe migraine attack. |
| Secondary | Return to Normal Function at 1 Hour Postdose | 1 hour after administration of study treatment | Average treatment effect of rimegepant 75 mg relative to placebo on the proportion of participants with normal function 1 hour after treatment. |
| Secondary | Return to Normal Function at 2 Hours Postdose | 2 hours after administration of study treatment | Average treatment effect of rimegepant 75 mg relative to placebo on the proportion of participants with normal function 2 hours after treatment. |
| Secondary | Sustained Pain Freedom From 2 to 24 Hours Postdose | 2 to 24 hours after administration of study treatment | Average treatment effect of rimegepant 75 mg relative to placebo on the proportion of participants with sustained pain freedom from 2 through 24 hours after treatment. |
| Secondary | Sustained Pain Freedom From 2 to 48 Hours Postdose | 2 to 48 hours after administration of study treatment | Average treatment effect of rimegepant 75 mg relative to placebo on the proportion of participants with sustained pain freedom from 2 through 48 hours after treatment. |
| Secondary | Sustained Pain Relief From 2 to 24 Hours Postdose | 2 to 24 hours after administration of study treatment | Average treatment effect of rimegepant 75 mg relative to placebo on the proportion of participants with sustained pain relief from 2 through 24 hours after treatment. |
| Secondary | Sustained Pain Relief From 2 to 48 Hours Postdose | 2 to 48 hours after administration of study treatment | Average treatment effect of rimegepant 75 mg relative to placebo on the proportion of participants with sustained pain relief from 2 through 48 hours after treatment. |
| Secondary | Freedom From Nausea at 1 Hour Postdose | 1 hour after administration of study treatment | Average treatment effect of rimegepant 75 mg relative to placebo on the proportion of participants free from nausea 1 hour after treatment among participants with nausea present at dosing. |
| Secondary | Freedom From Nausea at 2 Hours Postdose | 2 hours after administration of study treatment | Average treatment effect of rimegepant 75 mg relative to placebo on the proportion of participants free from nausea 2 hours after treatment among participants with nausea present at dosing. |
| Secondary | Freedom From Photophobia at 1 Hour Postdose | 1 hour after administration of study treatment | Average treatment effect of rimegepant 75 mg relative to placebo on the proportion of participants free from photophobia 1 hour after treatment among participants with photophobia present at dosing. |
| Secondary | Freedom From Photophobia at 2 Hours Postdose | 2 hours after administration of study treatment | Average treatment effect of rimegepant 75 mg relative to placebo on the proportion of participants free from photophobia 2 hours after treatment among participants with photophobia present at dosing. |
| Secondary | Freedom From Phonophobia at 1 Hour Postdose | 1 hour after administration of study treatment | Average treatment effect of rimegepant 75 mg relative to placebo on the proportion of participants free from phonophobia 1 hour after treatment among participants with phonophobia present at dosing. |
| Secondary | Freedom From Phonophobia at 2 Hours Postdose | 2 hours after administration of study treatment | Average treatment effect of rimegepant 75 mg relative to placebo on the proportion of participants free from phonophobia 2 hours after treatment among participants with phonophobia present at dosing. |
| Secondary | Rescue Medication Use Within 24 Hours Postdose | Within 24 hours after administration of study treatment | Rescue medication use within 24 hours post dose is a binary outcome indicating whether an evaluable participant used rescue medication after administration of study treatment and within 24 hours post dose. The treatment effect of rimegepant 75 mg relative to placebo will be summarized using the risk difference (RD) as the primary effect measure and the risk ratio (RR) as the secondary effect measure. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07906262/registered